Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Teladoc Health Stock Facing Increasing Competition

By MarketBeat.com (Steve Anderson )Stock MarketsDec 08, 2020 12:30AM ET
www.investing.com/analysis/teladoc-health-stock-facing-increasing-competition-200547143
Teladoc Health Stock Facing Increasing Competition
By MarketBeat.com (Steve Anderson )   |  Dec 08, 2020 12:30AM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Every situation produces a certain number of winners. Even disastrous situations like the coronavirus pandemic produced a few winners, especially for segments with “from-home” somewhere in their concepts. “Work-from-home,” “exercise-from-home,” and “shop-from-home” were among the big winners in the coronavirus, and for Teladoc (NYSE:TDOC), “see-the-doctor-at-home” proved to be one of the biggest slam-dunks around. However, every Cinderella story eventually features midnight, and for Teladoc, that midnight may have just sounded.

A Shot in the Chops

The latest hit to Teladoc's Cinderella story came when the glass slipper that was Stephens fell off, and with it, lowered Teladoc's rating from “overweight” to “equal weight.” The news that went with it wasn't all bad, but Stephens basically rang in with a note of the obvious: while Teladoc would continue to see patients, and see increases in such visits, it would no longer be the only big name in the field as new competitors would get in on the action.

Such an assessment isn't really a surprise, unless you feel like pointing out that someone should have pointed this out well before now. Teladoc's explosive growth is a signal for just about anyone else out there that both doctors and patients alike like the notion of having a doctor's appointment that takes place wholly inside the patient's own home.

That makes telehealth measures valuable to both parties, and improves the chance of adoption. Those who want to get in on the market, meanwhile, have a market that's increasingly amenable, and anyone who can get their product in front of customers first has the best chance of being adopted. Anyone who comes along after that has to make a much stronger case in order to affect change, and that's seldom easy without offering either many more features or a vastly reduced price.

Bucking the Trend

While the word from Stephens wasn't exactly good news, there is some good news to be had in the broader consensus. Based on our latest research, the wider analyst community finds Teladoc to be a “buy”, and has found it such for the last three months, with an improving ratio to boot. Three months ago, the company had 11 “hold” ratings and 16 “buy” ratings on it. A month ago, that improved to 11 “hold” and 17 “buy”, which is still where it is today. By way of reference, six months ago, the company was at 13 “hold” and just 11 “buy”, which made it merely a hold.

The consensus price target, meanwhile, has been on the rise ever since. Six months ago, it was at $161.17. Today, it's at $229.66, and that's quite feasible given the company's current price of $200.17 as of this writing.

It's worth noting that, while the consensus is still calling for a buy-in progress, the latest moves have been a little less bullish. So far this month—all six days of it—Goldman Sachs came out with coverage that called Teladoc “neutral,” while Bank of America maintained its own neutrality on the stock. The last bullish upgrade came from Robert W. Baird back in mid-November.

If You Offer It, They Will Stay Home

So, yes; it's a safe bet that Teladoc will see increasing competition in the months to come. Why not? It's already abundantly proven that doctors and patients alike are pretty happy with telemedicine options. The market is there; why wouldn't other businesses want to try and carve out a slice of that market pie for themselves?

However, even as other competitors step into the market, they will likely find it comparatively inhospitable. Those who already have Teladoc systems in place will need to be counter-sold, and most marketing operations will make it clear that that's the biggest challenge. In counter-selling, not only does the sales rep have to convince the customer that they're worth buying, but they're also so worth buying that it's worth clearing out the last guy. That means overcoming customer inertia; no one wants to make those kinds of changes without a compelling reason to do so. This is particularly true in a heavily-regulated field like medicine; it's already a challenge to bring in new technology while making sure all the government-related punctilio are observed.

Stephens is right that there will be growing competition to Teladoc. However, that competition is going to have to scramble to get to people Teladoc hasn't already hit. Unless that hypothetical competition can find a lot of untapped market, or make itself such a value that current Teladoc customers will throw over an already-established solution, the competition's impact on the market will be incidental at best.

Original Post

Teladoc Health Stock Facing Increasing Competition
 

Related Articles

Teladoc Health Stock Facing Increasing Competition

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email